Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19262172 | RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | July 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19203759 | SYSTEM FOR PRODUCING AND DELIVERING CONTACTLESS VETERINARY PASSIVE IMMUNIZATION | May 2025 | November 2025 | Allow | 6 | 1 | 1 | No | No |
| 19053784 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19053808 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 18895059 | PRE-FUSION RSV F ANTIGENS | September 2024 | February 2026 | Abandon | 17 | 2 | 0 | No | No |
| 18798779 | RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | August 2024 | May 2025 | Allow | 9 | 1 | 0 | No | No |
| 18649981 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | April 2024 | January 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18629504 | Mutated Glycoprotein of Vesicular Stomatitis Virus | April 2024 | January 2025 | Allow | 9 | 2 | 0 | No | No |
| 18629466 | Mutated Glycoprotein of Vesicular Stomatitis Virus | April 2024 | March 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18629579 | Mutated Glycoprotein of Vesicular Stomatitis Virus | April 2024 | February 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18629097 | Mutated Glycoprotein of Vesicular Stomatitis Virus | April 2024 | January 2025 | Allow | 9 | 2 | 0 | No | No |
| 18610681 | RNA VACCINES AGAINST INFECTIOUS DISEASES | March 2024 | February 2025 | Allow | 11 | 1 | 1 | No | No |
| 18596426 | PRE-FUSION RSV F ANTIGENS | March 2024 | November 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18409645 | PREFUSION RSV F PROTEINS AND THEIR USE | January 2024 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18407208 | SYSTEM FOR DELIVERY OF INACTIVATED PATHOGENS FOR CONTACTLESS PASSIVE IMMUNIZATION | January 2024 | January 2025 | Allow | 12 | 2 | 1 | No | No |
| 18505534 | METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) | November 2023 | June 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18490287 | NOROVIRUS S PARTICLE BASED VACCINES AND METHODS OF MAKING AND USING SAME | October 2023 | September 2025 | Allow | 23 | 1 | 0 | No | No |
| 18485625 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18378021 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY | October 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18552107 | ANTIBODIES TO SARS-COV-2 | September 2023 | October 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18463736 | NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF | September 2023 | February 2025 | Allow | 17 | 2 | 0 | No | No |
| 18356837 | DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYS | July 2023 | September 2025 | Allow | 26 | 1 | 0 | No | No |
| 18355601 | ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | July 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18338612 | ZIKA VIRUS VACCINE | June 2023 | August 2025 | Allow | 26 | 1 | 1 | No | No |
| 18335872 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | July 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18335874 | METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZA | June 2023 | August 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18323215 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | November 2023 | Allow | 6 | 4 | 0 | No | No |
| 18323192 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | June 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18323185 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | December 2023 | Allow | 7 | 3 | 0 | Yes | No |
| 18323177 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | December 2023 | Allow | 6 | 4 | 0 | No | No |
| 18323166 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | September 2023 | Allow | 5 | 3 | 0 | Yes | No |
| 18323209 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | May 2023 | May 2025 | Abandon | 24 | 3 | 0 | No | No |
| 18302400 | RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF | April 2023 | August 2024 | Allow | 16 | 1 | 0 | No | No |
| 18043442 | Hemagglutinin Modifications for Improved Influenza Vaccine Production | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18042093 | COMPOSITIONS AND METHODS FOR VACCINATION OF JUVENILES AGAINSTRESPIRATORY SYNCYTIAL VIRUS INFECTION | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18040523 | SARS-COV-2 RAPID SEQUENCE-BASED DIAGNOSTIC ASSAY WITH SENSORS OF IMMUNE ACTIVATION AND THE VIRAL MICROBIOTA | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18007092 | Amino Acid Sequence Derived from Sars-Cov-2 and Use Thereof | January 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18003547 | VACCINE COMBINATION AGAINST REPIRATORY SYNCYTIAL VIRUS INFECTION | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18087745 | MICRONEEDLE CONTAINING INFLUENZA VACCINE AND INFLUENZA VACCINE PATCH CONTAINING THE SAME | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18068867 | STABILIZED RSV F PROTEINS AND USES THEREOF | December 2022 | October 2024 | Allow | 22 | 2 | 0 | No | No |
| 18082456 | IMMUNOGENIC COMBINATIONS | December 2022 | August 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17927649 | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | November 2022 | January 2026 | Allow | 38 | 2 | 1 | Yes | No |
| 17920416 | IMMUNIZATION AGAINST SARS-COV-RELATED DISEASES | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17919733 | RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE | October 2022 | March 2026 | Allow | 41 | 1 | 1 | No | No |
| 18046743 | RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETO | October 2022 | August 2024 | Allow | 22 | 2 | 0 | No | No |
| 17931629 | ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USE | September 2022 | September 2024 | Allow | 24 | 0 | 1 | No | No |
| 17818887 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE | August 2022 | March 2025 | Allow | 31 | 1 | 0 | No | No |
| 17816495 | SARS-COV-2 CHIMERIC VLP VACCINE COMPOSITION, EXPRESSING VECTOR AND USE THEREOF | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17860833 | SERUM-FREE SUSPENSION SYSTEM FOR LENTIVIRAL PRODUCTION | July 2022 | March 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17848247 | PRE-FUSION RSV F ANTIGENS | June 2022 | October 2025 | Abandon | 40 | 6 | 0 | Yes | No |
| 17848230 | PRE-FUSION RSV F ANTIGENS | June 2022 | June 2024 | Allow | 24 | 4 | 0 | Yes | No |
| 17831928 | FCRn-Targeted Mucosal Vaccination Against RSV | June 2022 | March 2024 | Allow | 22 | 2 | 0 | No | No |
| 17736755 | Identification of inhibitor peptides to bind with N-terminal Spike (S) and nonstructural protein (NSP) sequences of SARS-COV2 B.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy | May 2022 | September 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17674683 | RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYANHYDRIDE NANOPARTICLE VACCINE | February 2022 | March 2026 | Allow | 49 | 1 | 0 | No | No |
| 17665704 | NUCLEIC ACID BASED COMBINATION VACCINES | February 2022 | March 2026 | Allow | 49 | 6 | 0 | Yes | No |
| 17575829 | CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE | January 2022 | November 2024 | Allow | 34 | 1 | 0 | No | No |
| 17626415 | METHODS FOR GROWING AFRICAN SWINE FEVER VIRUS IN FETAL PORCINE LUNG ALVEOLAR MACROPHAGE CELLS | January 2022 | December 2025 | Allow | 47 | 2 | 0 | No | No |
| 17622468 | IMMUNOGEN | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17554232 | AFRICAN SWINE FEVER VACCINE | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17546835 | INFLUENZA B VIRUS REPLICATION FOR VACCINE DEVELOPMENT | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17529665 | Constructs for Enhancing Immune Responses | November 2021 | April 2025 | Allow | 41 | 0 | 0 | No | No |
| 17594394 | PROPHYLACTIC TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION WITH AN ADENOVIRUS BASED VACCINE | October 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17450348 | STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINS | October 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17472721 | Self-assembled protein nanoparticle and its applications thereof | September 2021 | April 2025 | Abandon | 43 | 2 | 1 | Yes | No |
| 17458136 | RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE | August 2021 | December 2024 | Allow | 39 | 3 | 0 | No | No |
| 17296879 | NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE | May 2021 | August 2025 | Allow | 51 | 1 | 1 | No | No |
| 17289827 | RSV VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17241957 | BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION | April 2021 | January 2026 | Allow | 57 | 4 | 1 | Yes | No |
| 17259844 | RECOMBINANT ROTAVIRUS EXPRESSION SYSTEM AND RECOMBINANT ROTAVIRUSES | January 2021 | August 2024 | Allow | 43 | 2 | 1 | No | No |
| 17134663 | Utilizing Vaccines to Treat Cancer and Enhance the Success Rate of Cancer Immunotherapy | December 2020 | January 2026 | Allow | 60 | 3 | 1 | No | No |
| 17054104 | REVERSE PEPTIDE VACCINE | November 2020 | July 2024 | Allow | 45 | 2 | 1 | No | No |
| 17052707 | VACCINE COMPOSITION | November 2020 | June 2025 | Allow | 55 | 4 | 1 | No | No |
| 16930079 | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome | July 2020 | October 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16761869 | MEANS AND METHOD FOR PRODUCING AND PURIFYING VIRAL VECTORS | May 2020 | July 2024 | Allow | 51 | 3 | 1 | No | No |
| 16752328 | COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOF | January 2020 | March 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16620459 | METHODS FOR PREDICTING THE USEFULNESS OF DISEASE SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | December 2019 | June 2024 | Allow | 54 | 2 | 0 | Yes | Yes |
| 16500707 | PROTEIN ANTIGENS AND USES THEREOF | October 2019 | January 2025 | Allow | 60 | 1 | 1 | No | No |
| 16483113 | NASOPHARYNGEAL PROTEIN BIOMARKERS OF ACUTE RESPIRATORY VIRUS INFECTION AND METHODS OF USING SAME | August 2019 | October 2024 | Allow | 60 | 3 | 1 | No | No |
| 16235030 | VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS | December 2018 | August 2019 | Allow | 7 | 1 | 0 | No | No |
| 16091257 | VACCINE AGAINST RSV | October 2018 | December 2019 | Allow | 14 | 1 | 0 | No | No |
| 15940432 | METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES | March 2018 | December 2018 | Allow | 9 | 1 | 0 | No | No |
| 15795545 | METHODS AND COMPOSITIONS FOR STABILIZING DRIED BIOLOGICAL MATERIALS | October 2017 | February 2019 | Allow | 16 | 2 | 0 | Yes | No |
| 15796500 | VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALS | October 2017 | August 2018 | Allow | 9 | 1 | 0 | No | No |
| 15548883 | ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTION | August 2017 | December 2018 | Allow | 16 | 2 | 1 | No | No |
| 15638820 | RSV G PROTEIN SPECIFIC ANTIBODIES | June 2017 | March 2018 | Allow | 8 | 2 | 0 | Yes | No |
| 15517693 | METHODS OF TREATING RSV INFECTIONS | April 2017 | September 2019 | Allow | 30 | 2 | 0 | Yes | No |
| 15327142 | THERMOSTABLE FREEZE DRIED ROTAVIRUS VACCINE FORMULATION AND PROCESS TO PREPARE THEREOF | January 2017 | August 2019 | Allow | 31 | 2 | 0 | No | No |
| 15327102 | THERMOSTABLE SPRAY DRIED ROTAVIRUS VACCINE FORMULATION AND PROCESS THEREOF | January 2017 | September 2019 | Allow | 32 | 2 | 0 | No | No |
| 15383578 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS | December 2016 | September 2019 | Allow | 32 | 2 | 1 | No | No |
| 14913879 | METHOD OF DETERMINING RESISTANCE TO INFLUENZA VIRUS | February 2016 | January 2018 | Allow | 23 | 2 | 0 | Yes | No |
| 14890994 | VACCINES FOR DISEASES CAUSED BY VIRUSES OF THE FAMILY OF REOVIRIDAE | November 2015 | November 2017 | Allow | 24 | 2 | 1 | Yes | No |
| 14815131 | RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED IN TRANS | July 2015 | September 2017 | Allow | 26 | 2 | 1 | Yes | No |
| 14553957 | Virus Causing Respiratory Tract Illness in Susceptible Mammals | November 2014 | December 2015 | Allow | 13 | 2 | 0 | No | No |
| 14401758 | Influenza Vaccine Constructs | November 2014 | December 2016 | Allow | 25 | 1 | 1 | No | No |
| 14387476 | Epitope-Scaffold Immunogens Against Respiratory Syncytial Virus (RSV) | September 2014 | May 2017 | Allow | 32 | 2 | 1 | Yes | No |
| 14359291 | RSV G PROTEIN SPECIFIC ANTIBODIES | May 2014 | March 2017 | Allow | 34 | 2 | 1 | Yes | No |
| 14270237 | METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES | May 2014 | February 2016 | Allow | 21 | 1 | 0 | No | No |
| 14161430 | INFLUENZA B VIRUSES HAVING ALTERATIONS IN THE HEMAGGLUTININ POLYPEPTIDE | January 2014 | February 2015 | Allow | 12 | 1 | 0 | No | No |
| 14009049 | NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES | September 2013 | August 2015 | Allow | 23 | 1 | 0 | No | No |
| 14026567 | ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE | September 2013 | October 2015 | Allow | 25 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HILL, MYRON G.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HILL, MYRON G works in Art Unit 1671 and has examined 158 patent applications in our dataset. With an allowance rate of 94.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner HILL, MYRON G's allowance rate of 94.9% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by HILL, MYRON G receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HILL, MYRON G is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +3.7% benefit to allowance rate for applications examined by HILL, MYRON G. This interview benefit is in the 26% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 31.0% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 65.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 48.4% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 20.3% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.7% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.